

First Clinical Results Using Seracam® for Small Organ Imaging Presented at EANM'24

London, UK, 23 October 2024. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medical technology company developing a unique portable hybrid gamma-optical camera for medical imaging, announces that its clinical partners from the University Malaya Medical Centre and Taylor’s University, Malaysia have presented the first clinical results using Seracam® for small organ imaging at the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, Germany. The study involves a comparison of the diagnostic accuracy and resolution of radiopharmaceutical uptake between Seracam® and standard gamma cameras, using images obtained from the same patient on the same day.

The e-poster (number EP-0715) available throughout the conference titled “**Small Field-of-View Imaging Using a Hybrid Optical-Gamma Camera: Specifications and First Clinical Results**” provides an overview of the study design, performance settings and image characterisation. It also includes case studies and images from a range of patients including parathyroid, lymphoscintigraphy and bone scan investigations, alongside comparable images taken with a standard gamma camera in a nuclear medicine department.

The findings demonstrate that Seracam® is highly suited to small field-of-view imaging applications such as thyroid and parathyroid using Tc-99m and I-131; sentinel node localisation studies and bone spot views, among others.

The investigators concluded that Seracam® complements the large field-of-view cameras and in some applications may provide an improved solution for small organ imaging without the use of the larger, more expensive systems. The compact nature and portability of Seracam® offers the potential to integrate scintigraphy within clinical pathways outside the nuclear medicine department such as surgical and intensive care settings.

The study is ongoing and will recruit up to 150 patients in total. Investigation of further clinical applications using different radionuclides are underway. The study will also determine how the fusion of the gamma and optical images can be used to best effect.

Chief Executive of Serac Imaging Systems, Mark Rosser, said:

“These first user cases in small organ imaging have yielded highly encouraging results for the camera both in terms of the images generated and feedback from the camera operators. We look forward to seeing more results from the ongoing study and evaluating the impact of using this ground-breaking molecular imaging camera on patient care. These early results demonstrate that the combination of the co-aligned gamma-optical hybrid imaging capability, alongside the compact size and portability of the camera have real potential to improve and expand nuclear imaging options, diagnosis, and outcomes for patients.”

Dr Aik Hao Ng, clinical medical physicist and senior lecturer at the University of Malaya and one of the lead investigators on the study commented:

“The compact nature and portability of Seracam brings many practical benefits and offers the potential to integrate scintigraphy within clinical pathways beyond the nuclear medicine department such as surgical and intensive care settings. We look forward to assessing Seracam in a wider variety of clinical investigations and with different isotopes to determine where it is likely to have the most benefit for patients.”

The e-poster is authored by Intan Noorliyana Md Musidek, Aik Hao Ng, and Mohammad Nazri Md Shah of the Faculty of Medicine at the University of Malaya, Chai Hong Yeong from the Taylor's University, Malaysia and Alan Perkins from the Radiological Sciences Department, School of Medicine, University of Nottingham.

- ENDS -

Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

For more information, please contact:

Mark Rosser, Chief Executive Officer

+44 (0)208 948 0000

info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010 820

francettacarr@seraclifesciences.com

Follow us on LinkedIn here: www.linkedin.com/company/seracimagingssystems

Notes to Editors

The abstract "SFoV Imaging Using a Hybrid Optical-Gamma Camera (HGC): Specifications and First Clinical Result" is accessible in the [EANM '24 Abstract](#) book accessible until 7th November and on our website [here](#).

About EANM'24: <https://eanm24.eanm.org/>

About Serac Imaging Systems and Seracam®

Serac Imaging Systems Ltd is the medical technology company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A unique feature of Seracam® is the real-time overlay of a gamma image with an optical image of the same anatomical location under examination. Such highly versatile and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions.

Seracam® is a UK and EU registered trademark. Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimagingssystems.com